Cancercompass News: prostate cancer
|
|
11/13/2008 Watson Announces The NDA For A 6-Month Formulation Of Trelstar Accepted For Filing By FDA For The Treatment Of Advanced Prostate Cancer CORONA, Calif. -- Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today announced that its New Drug Application (NDA) for a 6-month formulation of TRELSTAR(R) (triptorelin pamoate), a luteinizing hormone releasing hormone (LHRH) agonist, has been accepted for filing by the U.S. Food and Drug Administration (FDA). Watson is seeking marketing approval of this TRELSTAR(R) formulation for the palliative treatment of advanced prostate cancer. Watson anticipates that FDA will take action on its application in the third quarter 2009. The sustained-release formulation of TRELSTAR(R) is designed to suppress the production of testosterone in men with advanced prostate cancer over 6 months. Prostate can... Read more at this website... 11/10/2008 Marillion Acquires Exclusive Worldwide Rights To 177Lu-AMBA , A First In Class Targeted Radiotherapeutic For Advanced Prostate Cancer MALVERN, Pa. & PRINCETON, N.J. -- Marillion Pharmaceuticals Inc. and Bracco Imaging S.p.A., one of the world's leading companies in the diagnostic imaging business and part of the Bracco Group, announced today that the two companies have entered into a license agreement granting Marillion exclusive worldwide rights to complete clinical development and to commercialize Bracco's (177)Lu-AMBA for the treatment of hormone-resistant prostate and advanced (metastatic) breast cancers. According to the World Health Organization (WHO), prostate and breast cancers affect more than 4 million patients via new diagnoses each year. Prostate cancer is a chronic disease occurring in men over 50 years old. The cancer evolves in two phas... Read more at this website... 11/10/2008 New Data Suggest Potential Benefits Of Targeted Tissue Cooling During Prostate Surgery SAN DIEGO -- Cardium Therapeutics and its operating unit InnerCool Therapies, Inc., today announced that it has developed a pelvic cooling catheter system called UroCool(TM), which is designed to induce localized cooling during surgery for prostate cancer (radical prostatectomy). The new technology is being applied in collaboration with renowned prostate surgeon, Thomas E. Ahlering, M.D., Professor and Vice Chair of the Department of Urology at the University of California, Irvine and is the subject of an exclusive licensing agreement with the University of California. A regulatory application for FDA 510(k) clearance of InnerCool's UroCool(TM) catheter is expected to be submitted in the first quarter of 2009. Dr. Ah... Read more at this website... 11/09/2008 The Influence Of Statin Medications On Prostate-Specific Antigen Levels BERKELEY -- Christopher P. Evans, M.D. reports on the following: Dr. Robert J. Hamilton and associates report statin use lowers PSA levels, and as a result may confound the detection of prostate cancer (CaP) in these patients. In this study, the investigators sought to determine the effect of statins on serum PSA levels. A retrospective study population of 1,214 men who had filled an outpatient prescription for a statin between 1990 and 2006 was identified in the Durham VA Medical Center database. Men were excluded if they had a diagnosis of CaP, underwent treatment for CaP, had a TURP or prostatitis or were treated with either dutasteride or finasteride. Pre- and post-statin initiation PSA and LDL levels were required.... Read more at this website... 11/06/2008 LabCorp Presents Positive Results On GST-Pi/APC Methylation Test For Detection Of Prostate Cancer LabCorp presents positive results on GST-Pi/APC methylation test for detection of prostate cancer OncoMethylome's methylation technology for improving the detection of prostate cancer was validated in a study presented by LabCorp. Dr. Steven Anderson, Senior Laboratory Director, Center for Molecular Biology and Pathology, and Sr. Vice President of LabCorp presented the GST-Pi and APC methylation results from more than 400 core biopsies representing a spectrum of histopathology findings ranging from benign tissues to prostate cancers. Confirming results of studies reported in peer-review journals, the assay demonstrated a sensitivity of 90.3% and specificity of 88.6% for the detection of prostate cancer. In many cases be... Read more at this website... 10/30/2008 Approaching Cancer Aggressively In December 2006, I was diagnosed with a serious case of prostate cancer-serious because it was graded on a Gleason Scale (which measures the level of aggressiveness of the cancer cells) as a 9 out of a possible 10. My conscious choice at that time was to "keep it quiet" because I didn't want anyone "hanging crepe," showering sympathy, or any of the other most common reactions. In retrospect, I would call that a somewhat self-serving decision because there was probably some benefit my friends could derive from knowing about my case; how did I get cancer, and how was I going to pursue it? Looking at it more closely, it would be very accurate to say that at that early stage, I knew next to nothing about the answers to either of those qu... Read more at this website... 10/27/2008 National Cancer Institute Says No Prostate Benefit From Vitamin E, Selenium WASHINGTON -- The U.S. government is stopping a major study of whether vitamin E and selenium prevent prostate cancer - because the supplements aren't working and there's a hint of risk. More than 35,000 men age 50 and older have been taking one or both supplements or dummy pills for several years as part of a study called the SELECT trial. But the National Cancer Institute announced Monday that they will be getting letters in the next few days telling them to stop: An early review of the data shows neither supplement, taken alone or together, is preventing prostate cancer. Of more concern, slightly more users of vitamin E alone were getting prostate cancer - and slightly more selenium-only users were getting diabetes, the NCI said... Read more at this website... 10/27/2008 PCA3 Test May Help Distinguish Aggressive Prostate Cancer ARNHEM, The Netherlands -- The number of prostate cancer cases is increasing rapidly. Fortunately not all these tumours need to be operated - some are slow growing or indolent. The question remains: how do we reliably establish which tumour is aggressive and which is not? The answer may well be given by the PCA3 (Prostate Cancer Gene 3) test, a breakthrough in the diagnosis of prostate cancer. The genetic test was developed in the laboratory of the Radboud University in Nijmegen (NL) by a team headed by Professor Jack Schalken. PCA3 is a new tool available in a simple urine test to help make better biopsy decisions - in combination with Prostate Specific Antigen (PSA) - in the diagnosis of prostate cancer. It is avail... Read more at this website... 10/27/2008 Doctors Test Advanced Tool For Treating Prostate Cancer-technology Designed To Confirm Precise Brachytherapy Treatment ST. LOUIS -- Leading radiation oncologists are using the TargetScan Touch(TM) system to deliver radioactive seed therapy in the prostate. The innovative technology is based on a motionless probe which stabilizes the prostate during procedures. With the gland stabilized, physicians use a touch-screen interface and 3-D ultrasound images to map and confirm placement of radiation. Unveiled recently at the 2008 American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting, the TargetScan Touch(TM) has been tested at several of the nation's leading medical centers, including Emory University School of Medicine. "This technology delivers two important benefits. First, a stabilized prostate; second, the abil... Read more at this website... |
